Drug Profile
AB 506
Alternative Names: AB-506Latest Information Update: 01 Mar 2020
Price :
$50
*
At a glance
- Originator Baruch S. Blumberg Institute; Drexel University College of Medicine
- Developer Arbutus Biopharma
- Class Antivirals; Hepatoprotectants; Small molecules
- Mechanism of Action Capsid protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis B
Most Recent Events
- 08 Nov 2019 Efficacy and adverse events data from a phase Ia/IIb trial in Acute hepatitis presented at 70th Annual Meeting of the American Association for the Study of Liver Diseases (AASL-2019)
- 22 Oct 2019 Arbutus Biopharma planned trial in a phase-I trial in Healthy volunteers in New Zealand (PO) was terminated before initiation due to discontinuation of clinical development of AB 506 (ACTRN12619001255178)
- 10 Oct 2019 Discontinued - Phase-I for Hepatitis B treatment (In volunteers) in Australia (PO)